X4 Pharmaceuticals (NASDAQ:XFOR) Earns “Buy” Rating from HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $1.50 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 165.35% from the stock’s current price.

Separately, Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 0.8 %

XFOR stock opened at $0.57 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company’s 50 day simple moving average is $0.55 and its 200-day simple moving average is $0.62. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The firm has a market capitalization of $96.41 million, a PE ratio of -6.28 and a beta of 0.14.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently modified their holdings of XFOR. Barclays PLC lifted its stake in shares of X4 Pharmaceuticals by 196.0% during the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after buying an additional 183,861 shares during the period. XTX Topco Ltd lifted its stake in shares of X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after purchasing an additional 46,397 shares during the period. Jane Street Group LLC boosted its holdings in shares of X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after purchasing an additional 126,296 shares during the last quarter. State Street Corp boosted its holdings in shares of X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after purchasing an additional 189,105 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after purchasing an additional 81,968 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.